115 completed, 14 unknown, 13 terminated, 5 active not recruiting. 47 Phase 3, 42 Phase 2, 39 Phase 4, 14 Not applicable, 12 Phase 1.
Follow Alendronate: new trials by email Literature Review of Alendronate trials Research Report on Alendronate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Small Trial of Alendronate Impact on the Reservoir of HIV Alendronate, Placebo - HIV | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2026-07-08 | 2026-10-05 |
| Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes Romosozumab, Alendronate (Fosamax), Placebo Romosozumab - Osteoporosis, Post-menopausal | Phase 2 | Withdrawn | University of Pittsburgh | 2026-06-20 | 2026-06-04 | |
| Alendronate for Osteonecrosis in Adults With Sickle Cell Disease Alendronate Sodium - Sickle Cell Disease, Sickle Cell Anemia | Phase 2 | Recruiting | University of California, Davis | 30 | 2026-03-09 | 2026-07-16 |
| Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation Alendronate 70mg weekly - Cervix Cancer | Phase 1 / Phase 2 | Not yet recruiting | Dr. Itay GoorAryeh | 65 | 2025-12-01 | 2025-11-24 |
| Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis Alendronate, Ibandronate; Risedronate, Teriparatide - Osteoporosis, Osteoporosis, Postmenopausal | Not applicable | Completed | Khyber Medical University Peshawar | 40 | 2025-10-01 | 2026-08-13 |
| A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without Fractures Alendronate 70mg weekly - Osteoporosis in Post-menopausal Women | Phase 4 | Recruiting | Odense University Hospital | 1400 | 2025-02-21 | 2025-03-07 |
| Therapeutic Prospects of HMG-CoA Reductase Inhibitors, Atorvastatin and Rosuvastatin, in Osteoporotic Patients Alendronate 70 mg tablets, Atorvastatin, Rosuvastatin - Osteoporosis, Postmenopausal, Statin Therapy | Not applicable | Completed | Alkufa university\\collage of pharmacy | 65 | 2025-02-01 | 2026-07-21 |
| A Phase II Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage Osteonecrosis of the Femoral Head RAB001 high dose, RAB001 medium dose, RAB001 low dose - Osteonecrosis, Osteonecrosis of the Femoral Head | Phase 2 | Active not recruiting | ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. | 161 | 2024-12-24 | 2026-03-24 |
| A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027) Alendronate, Enlicitide Decanoate - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 36 | 2024-04-23 | 2025-02-18 |
| Treatment Exercises With Core Stability and Dynamic Resistance Exercise for Postmenopausal Women With Osteoporosis Alendronate, treatment exercises - Postmenopausal Osteoporosis | Not applicable | Completed | Cairo University | 60 | 2024-02-01 | 2024-06-26 |
| Precision Medicine Approach for Osteoporosis - Follow Up Study Alendronate, Teriparatide - Osteoporosis | Phase 4 | Enrolling by invitation | Paul F Netzel | 40 | 2024-02-01 | 2026-04-01 |
| Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study) Zoledronate or Alendronate - Osteoporosis, Postmenopausal | Active not recruiting | 424 General Military Hospital | 122 | 2023-11-28 | 2026-07-22 | |
| Efficacy and Safety of Minodronate in Patients With Low Back Pain Minodronate, Alendronate - Postmenopausal Osteoporosis | Phase 4 | Unknown | Peking University Third Hospital | 72 | 2023-01-01 | 2022-12-09 |
| Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease Denosumab, Alendronate Sodium - Nonalcoholic Fatty Liver, Osteoporosis, Postmenopausal | Phase 4 | Completed | Aristotle University Of Thessaloniki | 72 | 2022-12-23 | 2026-07-23 |
| A Multi-centre, Double-blind RCT to Investigate the Effect of Alendronate on Knee Function Following ACLR Alendronate (ALN), Placebo - ACL Reconstruction | Phase 4 | Recruiting | Chinese University of Hong Kong | 100 | 2022-12-22 | 2026-08-12 |
| Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis JMT103, Alendronate sodium, JMT103 placebo - Glucocorticoid Induced Osteoporosis | Phase 2 | Unknown | Shanghai JMT-Bio Inc. | 231 | 2022-06-15 | 2022-05-31 |
| Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover Teriparatide, Alendronate - Age-Related Osteoporosis | Phase 4 | Active not recruiting | Madhumathi Rao | 60 | 2022-03-21 | 2026-05-14 |
| The Optimal Sequential Therapy After Long Term Denosumab Treatment zoledronate, Alendronate and Zoledronate - Osteoporosis | Phase 4 | Completed | National Taiwan University Hospital | 44 | 2022-01-10 | 2025-11-19 |
| To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk SAL056 (56.5μg), Alendronate - Postmenopausal Women With Osteoporosis | Phase 3 | Completed | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 493 | 2021-12-03 | 2025-06-25 |
| Phase IV Clinical Trial to Evaluate Efficacy and Safety of MASI BONE S (Alendronate Sodium Trihydrate) in Postmenopausal Women With Osteoporosis Masibone S, Fosamax - Osteoporosis | Phase 4 | Unknown | Yonsei University | 170 | 2021-07-02 | 2022-05-31 |
Showing 20 of 157. Sign in to see all of them.
Osteoporosis (89) · Osteoporosis, Postmenopausal (32) · Bone Diseases, Metabolic (26) · Fractures, Bone (10) · Bone Resorption (5) · Bone Diseases (4) · Cystic Fibrosis (4) · Breast Neoplasms (3) · Chronic Periodontitis (3) · HIV Infections (3) · Hyperparathyroidism, Primary (3) · Hypogonadism (3) · Osteonecrosis (3) · Prostatic Neoplasms (3) · Rare Diseases (3)
Organon and Co (15) · Amgen (7) · Massachusetts General Hospital (7) · Merck Sharp & Dohme LLC (5) · Columbia University (4) · Chinese University of Hong Kong (3) · Government Dental College and Research Institute, Bangalore (3) · Hoffmann-La Roche (3) · Medical University of South Carolina (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Eli Lilly and Company (2) · GlaxoSmithKline (2) · Helen Hayes Hospital (2) · Istituto Auxologico Italiano (2) · Mylan Pharmaceuticals Inc (2)
United States (59) · Canada (9) · China (7) · Denmark (7) · Brazil (6) · Hong Kong (6) · Germany (5) · Italy (5) · Taiwan (5) · Argentina (4) · Australia (4) · Belgium (4) · France (4) · Greece (4) · Mexico (4)
Deborah A Bowlby, M.D. (3) · Athanasios D Anastasilakis, MD, PhD (2) · Elizabeth Shane, MD (2) · Thomas J Schnitzer, MD, PhD (2) · Alec Walker, MD, DrPH (1) · Alexander Kharlamov, M.D. (1) · Alexander Perrish, M.D. (1) · Alexandra Papaioannou, M.D. (1) · Amy Sun, MD, PhD (1) · Andreas Freitag, M.D. (1)
PMID 34231877, PMID 12795371, PMID 22152181, PMID 14500804, PMID 16093464, PMID 16449339, PMID 16495394, PMID 16684825, PMID 17164314, PMID 17333451, PMID 17371886, PMID 17708711, PMID 18003959, PMID 18025884, PMID 18039992, PMID 18495508, PMID 18536953, PMID 18539106, PMID 18641106, PMID 18767928, PMID 19401368, PMID 19594293, PMID 19732857, PMID 19918047, PMID 20200926, PMID 20533525, PMID 20649879, PMID 20922078, PMID 21148044, PMID 21448918, PMID 21542734, PMID 21593114, PMID 21891890, PMID 22127729, PMID 22235252, PMID 22353022, PMID 22839442, PMID 22848407, PMID 22932804, PMID 23024190, PMID 24382002, PMID 24429202, PMID 24619763, PMID 24636210, PMID 24719139, PMID 24798675, PMID 25033066, PMID 25882205, PMID 25929192, PMID 25933031
P50AR044855 (2), 2004 (1), 2008 (1), 2009 (1), 2015 (1), 2023 (1), K23AR048205 (1), K23HL148310 (1), N01AR002245 (1), P50AR039191 (1), R01AG072797 (1), R01AR046124 (1), R01AR056651 (1), R01DK061536 (1), R01DK080770 (1)